Form 4 for PTGX Protagonist Therapeutics, Inc
Accepted 2022-04-26 00:00:00 ET · period of report 2022-04-26 · accession 0001104659-22-050551 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2022-04-26 | 2022-04-26 | PTGX | PATEL DINESH V PH D | Pres, CEO, Dir | M - OptEx | $4.21 | +30.0K | 568.3K | +6% | +$126.3K |
| D | 2022-04-26 | 2022-04-26 | PTGX | PATEL DINESH V PH D | Pres, CEO, Dir | M - OptEx | $0.00 | -30.0K | 95.7K | -24% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2022-04-26 | M | A | 30,000 | $4.21 | 568,306 | D | — | — | (F1) Includes an aggregate of 459 shares acquired by the Reporting Person under the Issuer's 2016 Employee Stock Purchase Plan on March 9, 2022. |
| 2 | Derivative | Stock Option (right to buy) | 2022-04-26 | M | D | 30,000 | $0.00 | 95,742 | D | $4.21 · — to 2026-04-29 | 30,000 Common Stock | (F2) The stock option is vested in full. |